|
India News Releases
|
(India.CityRegions.Com, October 03, 2017 ) The biologics or a biopharmaceutical product means a pharmaceutical semi synthesized from different biological sources. In contrast to completely synthesized drugs, biologics are generally made up of living cells, gene components, sugars, proteins, nucleic acids, tissues, allergenic, and also vaccines. The useful components listed above are isolated from living sources and combined, to cure the disease with minimal side effects. Biologics products often represent the pioneer developments in biotechnology research and often aid medical practitioners in treating a variety of illnesses and conditions which presently have no other treatments available. Other factor such as the ability of biologics to facilitate complete cure of a disease with minimal side effects is boosting the growth of the market.
For more information about this report: http://www.reportsweb.com/global-biologics-market-analysis-and-forecast-2017-2025
Geographically, biologics have registered near double digit annual growth rate, whereas, the pharmaceutical drugs registered only single digit annual growth rate, in the past five years. This double digit growth was largely fuelled by the substantial investments of the major pharmaceutical companies, who realized the potential of the market quite early. The research study comprises of extensive analysis of various factors effecting the global biologics market. The entire market has been estimated and validated through three different approaches namely, by product, by therapeutic areas and by geographical destination. In terms of product, the market has been categorized into monoclonal antibody (mAbs), hormones, growth factors, fusion proteins, cytokines, therapeutic enzymes, vaccines, blood factors, and anticoagulants. The mAbs are the dominating other types in terms of sales and therapeutic enzymes is the highest growing type. In terms of therapeutic areas the market is segmented into oncology, cardiovascular, immunological diseases, infectious diseases, and metabolic diseases. The market is dominated by oncology related products and infectious diseases related products are expected to grow at the highest rate. In terms of geography, the market was segmented into North America, Europe, Latin America, Middle East, Africa and Rest of the World. In terms of sales, North America currently dominates the other geographical regions whereas, Middle East and Africa together are expected to grow at the highest rate. The key players which have significant contributions to the biologics market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, Gilead Sciences, Inc., AbbVie Inc., Amgen Inc., Lilly,Bristol-Myers Squibb, Novo Nordisk, Merck KGaA, Allergan, Plc, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, and Biocon Ltd. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the global biologics market.
The answers to the following key questions can be derived from this report- - What are the major market drivers, challenges and opportunities in the global biologics market and their case studies- - How did the biologics market evolve and what is its scope in the future- - What is the market share of the leading segments and sub-segments of the global biologics market in 2016 and 2025- - How will each segment of the global biologics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025- - What are the influencing factors that may affect the market share of the key players- - How will the industry evolve during the forecast period between 2016 and 2025- - What are the key developmental strategies implemented by the key players to stand out in this market- - Which geographical location will contribute to the highest sales of biologics-
Request Sample Copy at http://www.reportsweb.com/inquiry&RW00011014927/sample
This research report aims at answering various aspects of the global biologics market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion. The study considers the growth-share matrix model for a comprehensive study of the global biologics market and assesses the factors governing the same.
Table of Containts Executive Summary 1 Report Scope and Methodology 1.1. Scope of the Report 1.2. Global Biologics Market Segmentation 1.3. Key Learnings 1.4. Research Methodology 1.4.1. Key Data Points From Secondary Sources 1.4.2. Key Data Points From Primary Sources 1.4.3. Top-Down Approach (Segmental Analysis) 1.4.4. Bottom-Up Approach (Segmental Analysis) 1.4.5. Assumption and Limitations 1.4.6. Data and Prediction Modelling 2. Market Overview 2.1. Introduction 2.2. Market Dynamics 2.2.1. Market Drivers 2.2.2. Market Restraints 2.2.3. Market Opportunities 3. Global Biologics Market by Therapeutics 3.1. Overview 3.2. Market Trend Analysis 3.3. Oncology 3.4. Cardiovascular 3.5. Immunological Diseases 3.6. Infectious Diseases 3.7. Metabolic Diseases 4. Global Biologics Market by Product 4.1. Overview 4.2. Market Trend Analysis 4.3. Monoclonal Antibodies (mAbs) 4.4. Hormones 4.5. Growth Factors 4.6. Fusion Proteins 4.7. Cytokines 4.8. Therapeutic Enzymes 4.9. Blood Factors and Anticoagulants 4.10. Vaccines 5. Global Biologics Market by Geography 5.1. Overview 5.2. North America 5.2.1. The U.S. 5.2.2. Canada 5.3. Europe 5.3.1. Germany 5.3.2. France 5.3.3. The U.K. 5.3.4. Italy 5.3.5. Spain 5.4. Asia Pacific (APAC) 5.4.1. Japan 5.4.2. China 5.4.3. Australia 5.4.4. India 5.5. Latin America 5.6. Middle East Africa 5.7. Rest of the World (RoW) 6. Competitive Landscape 6.1. Key Developments and Strategies 6.2. Regulatory Body Clearance 6.3. New Product Launches and Developments 6.4. Merger & Acquisitions 6.5. Agreements, Joint Ventures and Partnerships 6.6. Business Expansion 6.7. Others 6.8. Patent Landscape 7. Company Profiles 7.1. AbbVie Inc. 7.2. Allergan Plc 7.3. Amgen Inc. 7.4. Astellas Pharma Inc. 7.5. AstraZeneca PLC 7.6. Bayer AG 7.7. Biocon Ltd. 7.8. Boehringer Ingelheim GmbH 7.9. Bristol-Myers Squibb Company 7.10. Eli Lilly and Company 7.11. F. Hoffmann-La Roche AG 7.12. Gilead Sciences, Inc. 7.13. GlaxoSmithKline Plc 7.14. Johnson & Johnson 7.15. Merck & CO., Inc. 7.16. Merck KGaA 7.17. Novartis AG 7.18. Novo Nordisk 7.19. Pfizer Inc. 7.20. Sanofi 7.21. Teva Pharmaceuticals Industries Limited
Inquire before Buying at http://www.reportsweb.com/inquiry&RW00011014927/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|